Todd JK, Bruhn FW. Severe Haemophilus influenzae infections: spectrum of disease. American Journal of Diseases in Children 1975;129:607-611.

Topley WW. The role of active or passive immunization in the control of enteric infection. Lancet 1938;1:181-186.

Trollfors B, Lagergard T, Claesson BA, Thomberg E, Martinell J, Schneerson R. Characterization of the serum antibody response to the capsular polysaccharide Haemophilus influenzae type b in children with invasive infections. Journal of Infectious Disease 1992;166:1335-1339.

Tudor-Williams G, Frankland J, Isaacs D, Mayon-White RT, MacFarlane JA, Rees DG, et al. Haemophilus influenzae type b conjugate vaccine trial in Oxford: implications for the United Kingdom. Archives of Disease in Childhood 1989;64:520-524.

Uhari M, Rantala H, Niemela M. Cluster of childhood Guillain-Barré cases after an oral poliovaccine campaign (letter). Lancet 1989;2:440-441.


Vadheim CM. Reduction of Hib disease in Southern California, 1983-1991. Program Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 1726, p. 398. Washington, DC: American Society for Microbiology; 1992.

Vadheim CM, Greenberg DP, Marcy SM, Froeschle J, Ward JI. Safety evaluation of PRP-D Haemophilus influenzae type b conjugate vaccine in children immunized at 18 months of age and older: follow-up study of 30,000 children. Pediatric Infectious Disease Journal 1990;9:555-561.


Walter EB. Moggio MV, Drucker RP, Wilfert CM. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease. Pediatric Infectious Disease Journal 1990:9:632-635.

Ward J, Cochi S. Haemophilus influenzae vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: W.B. Saunders; 1988.

Watemberg N, Dagan R, Arbelli Y, Belmaker I, Morag A, Hessel L, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatric Infectious Disease Journal 1991;10:758-763.

Weinberg GA, Granoff DM. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. Journal of Pediatrics 1988;113:621-631.

Weinberg GA, Granoff DM. Immunogenicity of Haemophilus influenzae type polysaccharide-protein conjugate vaccines in children with conditions associated with impaired antibody responses to type b polysaccharide vaccine. Pediatrics 1990;85(4 Pt 2):654-661.

Weinberg GA, Einhorn MS, Lenois AA, Granoff PD, Granoff DM. Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. Journal of Pediatrics 1987;111:22-27.

Weisman SJ, Cates KL, Allegretta GJ, Quinn JJ, Altman AJ. Antibody response to immunization with Haemophilus influenzae type b polysaccharide vaccine in children with cancer. Journal of Pediatrics 1987:111:727-729.


Yogev R, Arditi M, Chadwick EG, Amer MD, Sroka PA. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Pediatrics 1990;85(4 Pt 2):690-693.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement